TB-500 (Thymosin Beta-4 Fragment) Research Literature

In 1981, scientists at the National Institutes of Health isolated a small protein from calf thymus tissue that seemed to influence nearly every stage of tissue repair. Four decades later, that protein — thymosin beta-4 — and its synthetic fragment TB-500 have generated a body of published research spanning wound healing, cardiac repair, corneal regeneration, hair follicle growth, and systemic inflammation.

A comprehensive review published in the Annals of the New York Academy of Sciences described thymosin beta-4 as "one of the most active wound-healing molecules" studied — with documented effects across dermal repair, corneal healing, hair follicle regeneration, and cardiac tissue recovery.

TB-500's mechanism centers on a single protein interaction with enormous downstream effects. The peptide binds to G-actin — a building block of the cell's structural skeleton — and promotes its movement to wherever the body needs it for cellular migration and tissue repair.

This single interaction cascades into multiple pathways: it supports the migration of stem cells and progenitor cells to injury sites, promotes the formation of new blood vessels (angiogenesis), reduces inflammatory signaling during healing, and stabilizes neuromuscular junctions. Researchers have documented these mechanisms across multiple published studies.

The most extensively documented application of TB-500 in published research is wound healing. K.M. Malinda and colleagues conducted studies examining thymosin beta-4's effects on dermal wounds, finding significantly faster wound closure and reduced scarring in treated groups compared to controls. The researchers documented both the accelerated closure rate and the improved quality of the healed tissue.

In corneal injury models, researchers observed rapid re-epithelialization — the regeneration of the protective surface layer — following thymosin beta-4 application. These results were consistent enough to attract FDA review for wound healing applications.

Published studies have examined TB-500 in tendon, muscle, and ligament injury models. Researchers documented improved structural outcomes and functional recovery across multiple tissue types. The peptide's ability to promote cell migration to injury sites appears to be central to these effects — damaged tissue attracts TB-500-treated cells more effectively than untreated controls.

Fat grafting research by W. Li and colleagues examined thymosin beta-4's effects on adipose tissue survival after surgical grafting. The researchers found improved cellular growth and changes in the genetic profile of the tissue that explained increased fat survival rates in treated cases.

A Phase 1 clinical trial by Ruff and colleagues, published in the Annals of the New York Academy of Sciences in 2010, assessed the safety of synthetic thymosin beta-4 in 40 healthy volunteers. Participants received single intravenous doses of 42 mg, 140 mg, 420 mg, or 1,260 mg, followed by the same dose daily for 14 days.

The results: adverse events were infrequent, mild, or moderate. No dose-limiting toxicities were identified. No serious adverse events were reported across any dose level. This remains one of the most comprehensive human safety assessments of any research peptide.

A separate study examined venous stasis ulcers — chronic wounds that resist normal healing — and found that thymosin beta-4 treatment improved healing outcomes in patients with long-standing non-healing wounds.

The FDA is currently reviewing TB-500 for possible inclusion on the 503A Bulk Drug Substances List, which would create a clear legal pathway for compounding pharmacies. TB-500 has been on the World Anti-Doping Agency (WADA) prohibited list since 2011 due to its tissue-repair properties.

TB-500 and BPC-157 are the two most commonly studied tissue-repair peptides, but their research profiles are distinct. BPC-157 research is concentrated in gut, tendon, and musculoskeletal models with extensive work from the University of Zagreb. TB-500 research spans a broader range of tissue types — skin, cardiac, corneal, and hair follicle — with contributions from multiple international research groups. GHK-Cu, another repair peptide, focuses primarily on skin and wound healing. TB-500's systemic reach across tissue types is what distinguishes it in the published literature.